The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation

Thrombosis and Haemostasis

Volumn 107, Issue 2, 2012, Pages 356-368

  Hamesch, Karim ^a   Subramanian, Pallavi ^a   Li, Xiaofeng ^a   Dembowsky, Klaus ^b   Chevalier, Eric ^b   Weber, Christian ^a,c   Schober, Andreas ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Polyphor Ltd   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chemokines; Restenosis; Stents; Vascular remodelling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; COLLAGEN TYPE 1; POL 5551; RAPAMYCIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY INJURY; CONTROLLED STUDY; DRUG MEGADOSE; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HEALING IMPAIRMENT; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MACROPHAGE; MORPHOMETRICS; MOUSE; NEOINTIMA; NEUTROPHIL; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RE ENDOTHELIALISATION; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER;

ANGIOPLASTY; ANIMALS; APOLIPOPROTEINS E; BLOOD VESSEL PROSTHESIS IMPLANTATION; CAROTID ARTERIES; CELL MOVEMENT; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HUMANS; LYSOPHOSPHOLIPIDS; MACROPHAGES; MICE; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; POSTOPERATIVE COMPLICATIONS; PROTEINS; RECEPTORS, CXCR4; SIROLIMUS;

EID: 84863077298     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-07-0453     Document Type: Article

References (33)

1. Weintraub WS. The pathophysiology and burden of restenosis. Am J Cardiol 2007; 100: 3K-9K.
2. Garg S, Serruys PW. Coronary Stents. Current Status. J Am Coll Cardiol 2010; 56: S1-S42.
3. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel- eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
4. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
5. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
6. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286.
7. Farb A, Boam AB. Stent thrombosis redux--the FDA perspective. N Engl J Med 2007; 356: 984-987.
8. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-409.
9. Schober A, Knarren S, Lietz M, et al. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation 2003; 108: 2491-2497.
10. Zernecke A, Schober A, Bot I, et al. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 2005; 96: 784-791.
11. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 2008; 28: 1950-1959.
12. Subramanian P, Karshovska E, Reinhard P, et al. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ Res 2010; 107: 96-105.
13. Yokoi H, Yamada H, Tsubakimoto Y, et al. Bone marrow AT1 augments neointima formation by promoting mobilization of smooth muscle progenitors via plateletderived SDF-1. Arterioscler Thromb Vasc Biol 2009; 30: 60-67.
14. Massberg S, Konrad I, Schurzinger K, et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 2006; 203: 1221-1233.
15. Karshovska E, Zagorac D, Zernecke A, et al. A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury. J Thromb Haemost 2008; 6: 1812-1815.
16. Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008; 102: 209-217.
17. Robinson J, Demarco S, Gombert F, et al. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today 2008; 13: 944-951.
18. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004; 110: 790-795.
19. Sakihama H, Masunaga T, Yamashita K, et al. Stromal cell-derived factor-1 and CXCR4 interaction is critical for development of transplant arteriosclerosis. Circulation 2004; 110: 2924-2930.
20. Schober A, Hristov M, Kofler S, et al. CD34+CD140b+ cells and circulating CXCL12 correlate with the angiographically assessed severity of cardiac allograft vasculopathy. Eur Heart J 2011; 32: 476-484.
21. Mehta NN, Li M, William D, et al. The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels. Eur Heart J 2011; 32: 963-971.
22. Haribabu B, Richardson RM, Fisher I, et al. Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem 1997; 272: 28726-28731.
23. Karshovska E, Zernecke A, Sevilmis G, et al. Expression of HIF-1alpha in injured arteries controls SDF-1alpha mediated neointima formation in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 2540-2547.
24. Nemenoff RA, Simpson PA, Furgeson SB, et al. Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha. Circ Res 2008; 102: 1036-1045.
25. Fukuda D, Sata M, Tanaka K, et al. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005; 111: 926-931.
26. Inoue T, Sata M, Hikichi Y, et al. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation 2007; 115: 553-561.
27. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995; 267: 1034-1037.
28. Yu H, Stoneman V, Clarke M, et al. Bone marrow-derived smooth muscle-like cells are infrequent in advanced primary atherosclerotic plaques but promote atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 1291-1299.
29. Nakazawa G, Vorpahl M, Finn AV, et al. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging 2009; 2: 625-628.
30. Higo T, Ueda Y, Oyabu J, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. JACC Cardiovasc Imaging 2009; 2: 616-624.
31. Liehn EA, Schober A, Weber C. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 1891-1896.
32. Hristov M, Zernecke A, Bidzhekov K, et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007; 100: 590-597.
33. Volin MV, Joseph L, Shockley MS, et al. Chemokine receptor CXCR4 expression in endothelium. Biochem Biophys Res Commun 1998; 242: 46-53.